(John Hinderaker) Mylan NV has been taking a lot of abuse for sharply raising the price of its popular EpiPen. The Wall Street Journal explains the background on the price increase. It isn't, as I would have assumed, a case of patent protection. The patent on epinephrine ran out years ago. Rather, it turns out that keeping the anti-allergy dose sterile is difficult and expensive. Mylan's competitors have had a hard time
Source: Power LinePower Line